• Alzinova finalized seven US clinical sites for ADVANCE, its global Phase 2a trial of ALZ-101 in patients with early Alzheimer's disease.
• First participant enrollment is targeted around the turn of 2026/2027, subject to final protocol amendment acceptance and clinical trial material release.
• The study will evaluate the vaccine candidate in the United States, European Union and United Kingdom.
• ALZ-101 has FDA Investigational New Drug clearance to proceed in the US, alongside Fast Track designation intended to facilitate development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzinova AB published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.